September 23, 2024 02:49 PM EDT
Pharma
Law

J&J sub­sidiary files for third bank­rupt­cy to set­tle talc claims

Nicole DeFeudis

Editor

A John­son & John­son sub­sidiary filed for bank­rupt­cy in its third at­tempt to set­tle a vast ma­jor­i­ty of cas­es al­leg­ing its talc prod­ucts caused can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: Bris­tol My­ers’ tech chief on the promis­es and per­ils of AI bio

Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx

As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

Over a year af­ter FDA re­jec­tion, Bio­haven claims suc­cess in piv­otal mus­cle dis­ease study

Con­text makes a T cell en­gager deal; Gink­go Bioworks back­ers have a new SPAC

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times